American Journal of Kidney Diseases
Volume 51, Issue 6 , Pages 914-924 , June 2008

Cystatin C and Creatinine in an HIV Cohort: The Nutrition for Healthy Living Study

  • Clara Y. Jones, MD, MPH

      Affiliations

    • Tufts University School of Medicine, Boston, MA
    • Corresponding Author InformationAddress correspondence to Clara Y. Jones, MD, MPH, Tufts University School of Medicine, 200 Harrison Ave, Posner 415, Boston, MA 02111.
    • ,
  • Camille A. Jones, MD, MPH

      Affiliations

    • University of Arkansas School for Medical Sciences, Little Rock, AR
    • ,
  • Ira B. Wilson, MD, MSc

      Affiliations

    • Tufts University School of Medicine, Boston, MA
    • Tufts-New England Medical Center, Boston, MA
    • ,
  • Tamsin A. Knox, MD

      Affiliations

    • Tufts University School of Medicine, Boston, MA
    • ,
  • Andrew S. Levey, MD

      Affiliations

    • Tufts-New England Medical Center, Boston, MA
    • ,
  • Donna Spiegelman, PhD

      Affiliations

    • Harvard School of Public Health, Boston, MA
    • ,
  • Sherwood L. Gorbach, MD

      Affiliations

    • Tufts University School of Medicine, Boston, MA
    • ,
  • Frederick Van Lente, PhD

      Affiliations

    • Cleveland Clinic, Cleveland, OH.
    • ,
  • Lesley A. Stevens, MD, MS

      Affiliations

    • Tufts-New England Medical Center, Boston, MA

Received 11 July 2007 ,Accepted 3 January 2008.

References 

  1. Amin J, Kaye M, Skidmore S, Pillay D, Cooper D, Dore G. HIV and hepatitis C coinfection within the CAESAR Study. HIV Med. 2004;5:174–179
  2. Strader D. Coinfection with HIV and hepatitis C virus in injection drug users and minority populations. Clin Infect Dis. 2005;41(suppl 1):S7–S13
  3. DiGiambenedetto S, Baldini F, Cingolani A, Tamburrini E, Cauda R, DeLuca A. The influence of hepatitis C virus coinfection on the risk of lipid abnormalities in a cohort of HIV-1-infected patients after initiation of highly active antiretroviral therapy. J AIDS. 2004;36:641–642
  4. Schneider E, Glynn M, Kajese T, McKenna M. Epidemiology of HIV/AIDS—United States, 1981-2005. MMWR Morbid Mortal Wkly Rep. 2006;55:589–590
  5. Conaldi P, Biancone L, Bottelli A, et al. HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation. J Clin Invest. 1998;102:2041–2049
  6. Ray P, Liu X-H, Henry D, et al. Infection of human primary renal epithelial cells with HIV-1 from children with HIV-associated nephropathy. Kidney Int. 1998;53:1217–1229
  7. Kimmel P, Ferreira-Centeno A, Farkas-Szallasi T, Abraham A, Garrett C. Viral DNA in microdissected renal biopsy tissue from HIV infected patients with nephrotic syndrome. Kidney Int. 1992;43:1347–1352
  8. Bruggeman L, Ross M, Tanji N, et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol. 2000;11:2079–2087
  9. Marras D, Bruggeman L, Gao F, et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med. 2002;8:522–526
  10. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS. 2003;18:960–963
  11. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS. 2005;19:93–99
  12. Dieleman J, van Rossum A, Stricker B, et al. Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. J Acquir Immune Defic Syndr. 2003;32:135–142
  13. Tashima K, Horowitz J, Rosen S. Indinavir nephropathy. N Engl J Med. 1997;336:138–139
  14. Dieleman J, Sturkenboom M, Jambroes M, et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: The ATHENA cohort. Arch Intern Med. 2002;162:1493–1501
  15. Gardner L, Klein R, Szczech L, et al. Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J Acquir Immune Defic Syndr. 2003;34:320–330
  16. Gardner L, Holmberg S, Williamson J, et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:203–209
  17. Szczech L, Hoover D, Feldman J, et al. The association between renal disease and outcomes among HIV-infected women taking and not taking antiretroviral therapy. Clin Infect Dis. 2004;30:1150–1200
  18. Becker B, Schulman G. Nephrotoxicity of antiviral therapies. Curr Opin Nephrol Hypertens. 1996;5:375–379
  19. Gupta S, Eustace J, Winston J, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–1585
  20. Levey A, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  21. Stevens L, Levey A. Measurement of kidney function. Med Clin North Am. 2005;89:457–473
  22. Cocchetto D, Tschanz C, Bjornsson T. Decreased rate of creatinine production in patients with hepatic disease: Implications for estimation of creatinine clearance. Ther Drug Monit. 1983;5:161–168
  23. Kotler D. Nutritional alterations associated with HIV infection. J Acquir Immune Defic Syndr. 2000;25(suppl 1):S81–S87
  24. Filler G, Bokenkamp A, Hofmann W, LeBricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR—History, indications, and future research. Clin Biochem. 2005;8:1–8
  25. Massey D. Commentary: Clinical diagnostic use of cystatin C. J Clin Lab Anal. 2004;18:55–60
  26. Knox T, Spiegelman D, Skinner S, et al. Diarrhea and abnormalities of gastrointestinal function in a cohort of men and women with HIV infection. Am J Gastroenterol. 2000;95:3482–3489
  27. NHANES 2001-2002 Demographic, Examination, and Laboratory Data Files. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, and NHANES 2001-2002. http://www.cdc.gov/nchs/nhanes.htmAccessed 2006
  28. Coresh J, Astor B, McQuillan G, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis. 2002;39:920–929
  29. Levey A, Coresh J, Greene T, et al. Chronic Kidney Disease Epidemiology Collaboration Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254
  30. Levey AS, Coresh J, Greene T, et al. Chronic Kidney Disease Epidemiology Collaboration Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766–772
  31. Stevens LA, Manzi J, Levey AS, et al. Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. Am J Kidney Dis. 2007;50:21–35
  32. Selvin E, Manzi J, Stevens LA, Van Lente F, et al. Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. Am J Kidney Dis. 2007;50:918–926
  33. Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130:461–470
  34. Coresh J, Stevens LA, Greene T, et al. CKD-EPI: Serum cystatin C GFR estimation equation Pooled analysis of 3134 individuals. J Am Soc Nephrol. 2006;17:189A;(abstr)
  35. Lukaski H. Use of bioelectrical impedance analysis to assess human body composition: A review. In:  Livingston G editors. Nutritional Status Assessment of the Individual. Trumbull, CT: Food and Nutrition Press, Inc; 1989;p. 189–204
  36. NHANES III Laboratory Data File: US Department of Health and Human Services (DHHS). National Center for Health Statistics: Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III Laboratory Data File (CD-ROM) Public Use Data File Documentation Number 76200 (Available from National Technical Information Service (NTIS), Springfield, VA). Hyattsville, MD: Centers for Disease Control and Prevention; 1996;
  37. Correia L, Lima J, Gerstenblith G, et al. Correlation between turbidimetric and nephelometric methods of measuring C-reactive protein in patients with unstable angina or non-ST elevation acute myocardial infarction. Arq Bras Cardiol. 2003;81:133–136
  38. Roberts W, Moulton L, Law T, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications. Clin Chem. 2001;47:418–425
  39. Jones C, McQuillan G, Kusek J, et al. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 1998;32:992–999
  40. Finney H, Newman D, Thakkar H, Fell J, Price C. Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children. Arch Dis Child. 2000;82:71–75
  41. Galteau M-M, Guyon M, Gueguen R, Siest G. Determination of serum cystatin C: Biological variation and reference values. Clin Chem Lab Med. 2001;3981:850–857
  42. Uhlmann E, Hock K, Issitt C, et al. Reference intervals for plasma cystatin C in healthy volunteers and renal patients, as measured by the Dade Behring BN II system, and correlation with creatinine. Clin Chem. 2001;47:2031–2033
  43. Giordano T, Kramer J, Souchek J, Richardson P, El-Serag H. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: A cohort study, 1992-2001. Arch Intern Med. 2004;164:2349–2354
  44. Poynard T, Mathurin P, Lai C, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38:257–265
  45. Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C (A European collaborative study). Clin Infect Dis. 2004;38:128–133
  46. Moyle G. Mitochondrial toxicity: Myths and facts. J HIV Ther. 2004;9:45–47
  47. Authier F-J, Chariot P, Gherardi R. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve. 2005;32:247–260
  48. Moyle G. Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antiviral Ther. 2005;10:M47–M52
  49. El-Serag H, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002;36:1439–1445
  50. Vinge E, Lindergard B, Nilsson-Ehle P, Grubb A. Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults. Scand J Clin Lab Invest. 1999;59:587–592
  51. Villa P, Jimenez M, Soriano M-C, Manzanares J, Cassanovas P. Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients. Crit Care. 2005;9:R139–R143
  52. Tan G, Lewis A, James T, Altmann P, Taylor R, Levy J. Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes. Diabetes Care. 2002;25:2004–2009
  53. Samyn M, Cheeseman P, Bevis L, et al. Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantation. Liver Transplant. 2005;11:344–349
  54. Randers E, Ivarsen P, Erlandsen E, et al. Plasma cystatin C as a marker of renal function in patients with liver cirrhosis. Scand J Clin Lab Invest. 2002;62:129–134
  55. Randers E, Erlandsen E, Pedersen O, Hasling C, Danielsen H. Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. Clin Nephrol. 2000;54:203–209
  56. Perlemoine C, Beauvieux M-C, Rigalleau V, et al. Interest of cystatin C in screening diabetic patients for early impairment of renal function. Metabolism. 2003;52:1258–1264
  57. Orlando R, Mussap M, Plebani M, et al. Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem. 2002;48:850–858
  58. O'Riordan S, Webb M, Stowe H, et al. Cystatin C improves the detection of mild renal dysfunction in older patients. Ann Clin Biochem. 2003;40:648–655
  59. Larsson A, Malm J, Grubb A, Hansson L-O. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest. 2004;64:25–30
  60. Kyhse-Andersen J, Schmidt C, Nordin G, et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem. 1994;40:1921–1926
  61. Kazama J, Kutsuwada K, Maruyama H, Gejyo F. Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases. Nephron. 2002;91:13–20
  62. Hoek F, Kemperman F, Krediet R. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003;18:2024–2031
  63. Dharnidharka V, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis. 2002;40:221–226
  64. Demirtas S, Bozbas A, Akbay A, Yavuz Y, Karaca L. Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Clin Chim Acta. 2001;311:81–89
  65. Christensson A, Grubb A, Nilsson J, Norrgren K, Sterner G, Sundkvist G. Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy. J Intern Med. 2004;256:510–518
  66. Woitas P, Stoffel-Wagner B, Flommersfeld S, et al. Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem. 2000;46:712–715
  67. Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela S, Irjala K. Estimation of glomerular filtration rate in the elderly: A comparison of creatinine-based formulae with serum cystatin C. J Intern Med. 2004;256:70–78
  68. Hojs R, Bevc S, Antolinc B, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in the elderly. Int J Clin Pharm Res. 2004;XXIV:49–54
  69. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416–1421
  70. Colle A, Tavera C, Prevot D, et al. Cystatin C levels in sera of patients with human immunodeficiency virus infection. J Immunoassay. 1992;13:47–60
  71. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function—Measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473–2483
  72. Reisler RB, Jacobson L, Gupta S, et al. Chronic Kidney Disease and the Use of HAART. 12th Conference on Retroviruses and Opportunistic Infections (CROI). 2005;Boston, MA, February 22-25 (abstr 818)

 Because an author of this manuscript is an editor for AJKD, the peer-review and decision-making processes were handled entirely by an Associate Editor (Haiyan Wang, MD, Peking University) who served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

 Originally published online as doi:10.1053/j.ajkd.2008.01.027 on May 2, 2008.

PII: S0272-6386(08)00585-4

doi: 10.1053/j.ajkd.2008.01.027

American Journal of Kidney Diseases
Volume 51, Issue 6 , Pages 914-924 , June 2008

Article Tools

* Image Usage & Resolution